Fennec Pharmaceuticals Inc. - Common Stock (FENC)
9.2400
+2.4700 (36.48%)
NASDAQ· Last Trade: May 15th, 2:38 AM EDT
Fennec (FENC) Q1 2026 Earnings Call Transcript
Via The Motley Fool · May 14, 2026
These stocks are moving in today's sessionchartmill.com
Via Chartmill · May 14, 2026
Adherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow and early signs that recent sales force investments are increasing demand.
On the company’s first-
Via MarketBeat · May 14, 2026
Fennec Pharmaceuticals (NASDAQ:FENC) Q1 Beat Overshadowed by Surging Costschartmill.com
Via Chartmill · May 14, 2026
Fennec Pharmaceuticals (NASDAQ:FENC) Reports Q4 2025 Revenue Growth but Misses Earnings Estimateschartmill.com
Via Chartmill · March 24, 2026

This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands.
Via The Motley Fool · March 15, 2026

Euronet Worldwide runs a global payments platform, providing transaction processing and money transfer solutions across diverse markets.
Via The Motley Fool · March 15, 2026

This technology firm delivers IT infrastructure and managed solutions to major enterprises across multiple global industries.
Via The Motley Fool · March 5, 2026

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via Benzinga · November 6, 2023
Fennec Pharmaceuticals reported mixed Q2 2025 results, missing revenue estimates by 0.6% and posting a wider EPS loss. PEDMARK® growth and new accounts drove optimism despite financial underperformance.
Via Chartmill · August 14, 2025

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.
Via Benzinga · March 10, 2025

Via Benzinga · February 10, 2025

FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 13, 2024

These dirt cheap stocks under $10 have the potential to rise rapidly and create fortunes for bold investors.
Via InvestorPlace · July 29, 2024

Via Benzinga · May 14, 2024

FENC stock results show that Fennec Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 14, 2024

FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 21, 2024

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via Benzinga · March 21, 2024
